retatrutide parkinson disease clinical trial Parkinson's drug pipeline evolution and future directions | Michael S Okun posted on the topic A Big Week for GLP-1
Description
Recent Prog Horm Res
(2011) Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells
This includes 39% who report currently taking a GLP-1 and 10% who have taken one but stopped
It can only be accessed through participation in an approved clinical trial
Moitra M, Santomauro D, Collins PY, Vos T, Whiteford H, Saxena S, et al
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors it is not yet approved by the MHRA or EMA
